Last $0.01 USD
Change Today -0.005 / -33.33%
Volume 1.4M
PPCH On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

propanc health group corp (PPCH) Snapshot

Open
$0.01
Previous Close
$0.02
Day High
$0.02
Day Low
$0.01
52 Week High
05/22/14 - $0.47
52 Week Low
10/1/14 - $0.01
Market Cap
726.8K
Average Volume 10 Days
269.5K
EPS TTM
--
Shares Outstanding
72.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROPANC HEALTH GROUP CORP (PPCH)

Related News

No related news articles were found.

propanc health group corp (PPCH) Related Businessweek News

No Related Businessweek News Found

propanc health group corp (PPCH) Details

Propanc Health Group Corporation, a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic and colorectal cancer. Its products include PRP and PRP-DCM that are patented daily suppository formulation based on proenzymes. The company, formerly known as Propanc PTY LTD, was founded in 2007 and is based in Melbourne, Australia.

1 Employees
Last Reported Date: 10/15/13
Founded in 2007

propanc health group corp (PPCH) Top Compensated Officers

Chief Executive officer, Chief Financial offi...
Total Annual Compensation: $154.0K
Compensation as of Fiscal Year 2013.

propanc health group corp (PPCH) Key Developments

Propanc Health Group Corporation announced delayed annual 10-K filing

On 09/29/2014, Propanc Health Group Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Propanc Health Group Targets Cancer Patient Trials in 2015

Propanc Health Group Corporation announced its key strategic objectives for the development of its lead product, PRP. The company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers. After a detailed strategic review of its scientific and preclinical research, its development team determined I.V. injection as the preferred route of administration. This approach would be the best way to maximise results in future patient trials, by ensuring maximum exposure of the drug to the tumor site. This will help it to improve the results already observed in a Compassionate Use Study conducted by Dr. Kenyon at the Dove Clinic (UK). Based on the Company's strategic review, Propanc Health Group will conduct a number of animal studies in various tumor models. This will identify a target dose for future patient trials. Once it has assessed and identified the most effective dose in animals, it plans to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015. The Company is seeking to complete the relevant animal studies and undertake preparation for patient trials in 2015.

Propanc Health Group Corporation announced delayed 10-Q filing

On 05/13/2014, Propanc Health Group Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PPCH:US $0.01 USD -0.005

PPCH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PPCH.
View Industry Companies
 

Industry Analysis

PPCH

Industry Average

Valuation PPCH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROPANC HEALTH GROUP CORP, please visit www.propanc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.